Recarbrio
FDA approves MSD’s combo therapy Recarbrio for urinary tract and intra-abdominal infections
July 18, 2019Sales and Marketing FDA, MSD, Recarbrio, US, pharma, urinary tract
MSD has announced the approval from the FDA of its combination therapy Recarbrio (imipenem, cilastatin and relebactam) in the treatment …
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
